{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:25:06Z","timestamp":1789831506400,"version":"4.0.1"},"reference-count":60,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Incidence of cutaneous squamous cell carcinoma (cSCC) and actinic keratosis has increased worldwide, and non-steroidal anti-inflammatory drugs as celecoxib are considered for treatment. We show here strong anti-proliferative effects of celecoxib in four cSCC cell lines, while apoptosis and cell viability largely remained unaffected. Impeded apoptosis was overcome in combinations with agonistic CD95 antibody or TNF-related apoptosis-inducing ligand (TRAIL), resulting in up to 60% apoptosis and almost complete loss of cell viability. Proapoptotic caspase cascades were activated, and apoptosis was suppressed by caspase inhibition. TRAIL receptor (DR5) and proapoptotic Bcl-2 proteins (Puma and Bad) were upregulated, while anti-apoptotic factors (survivin, XIAP, cFLIP, Mcl-1, and Bcl-w) were downregulated. Strongly elevated levels of reactive oxygen species (ROS) turned out as particularly characteristic for celecoxib, appearing already after 2 h. ROS production alone was not sufficient for apoptosis induction but may play a critical role in sensitizing cancer cells for apoptosis and therapy. Thus, the full therapeutic potential of celecoxib may be better used in combinations with death ligands. Furthermore, the immune response against cSCC\/AK may be improved by celecoxib, and combinations with checkpoint inhibitors, recently approved for the treatment of cSCC, may be considered.<\/jats:p>","DOI":"10.3390\/ijms22073622","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T05:57:18Z","timestamp":1617170238000},"page":"3622","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["High ROS Production by Celecoxib and Enhanced Sensitivity for Death Ligand-Induced Apoptosis in Cutaneous SCC Cell Lines"],"prefix":"10.3390","volume":"22","author":[{"given":"Jiaqi","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology, Skin Cancer Center, Charit\u00e9 Universit\u00e4tsmedizin Berlin, 10117 Berlin, Germany"},{"name":"Department of Gynecology and Obstetrics, Jilin University, Changchun 130012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"May","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology, Skin Cancer Center, Charit\u00e9 Universit\u00e4tsmedizin Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claas","family":"Ulrich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology, Skin Cancer Center, Charit\u00e9 Universit\u00e4tsmedizin Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eggert","family":"Stockfleth","sequence":"additional","affiliation":[{"name":"Department of Dermatologie, Venerologie und Allergologie, Klinikum Bochum, Ruhr-Universit\u00e4t Bochum, 44791 Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8533-1519","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Eberle","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology, Skin Cancer Center, Charit\u00e9 Universit\u00e4tsmedizin Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s00405-014-3261-6","article-title":"Analysis of selected risk factors for nodal metastases in head and neck cutaneous squamous cell carcinoma","volume":"272","author":"Szewczyk","year":"2015","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/jdv.15845","article-title":"Advanced cutaneous squamous cell carcinoma: Real world data of patient profiles and treatment patterns","volume":"33","author":"Amaral","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/1097-0142(19950115)75:2+<667::AID-CNCR2820751409>3.0.CO;2-I","article-title":"Skin cancer in African Americans","volume":"75","author":"Halder","year":"1995","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","article-title":"Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics","volume":"26","author":"Kerr","year":"1972","journal-title":"Br. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family reunion","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nri2115","article-title":"Life and death in peripheral T cells","volume":"7","author":"Krammer","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/sj.cdd.4401160","article-title":"Many cuts to ruin: A comprehensive update of caspase substrates","volume":"10","author":"Fischer","year":"2003","journal-title":"Cell Death Differ."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2007.15.7198","article-title":"Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2\/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L\/TRAIL)","volume":"26","author":"Ashkenazi","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Eberle, J. (2019). Countering TRAIL Resistance in Melanoma. Cancers, 11.","DOI":"10.3390\/cancers11050656"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e2594","DOI":"10.1038\/cddis.2017.6","article-title":"Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells","volume":"8","author":"Bauer","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1038\/cddis.2013.344","article-title":"ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis","volume":"4","author":"Quast","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/mc.22924","article-title":"Crucial role of reactive oxygen species (ROS) for the proapoptotic effects of indirubin derivative DKP-073 in melanoma cells","volume":"58","author":"Zhivkova","year":"2019","journal-title":"Mol. Carcinog."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Soltan, M.Y., Sumarni, U., Assaf, C., Langer, P., Reidel, U., and Eberle, J. (2019). Key Role of Reactive Oxygen Species (ROS) in Indirubin Derivative-Induced Cell Death in Cutaneous T-Cell Lymphoma Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051158"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1021\/acs.analchem.7b05337","article-title":"Celecoxib Conjugated Fluorescent Probe for Identification and Discrimination of Cyclooxygenase-2 Enzyme in Cancer Cells","volume":"90","author":"Gurram","year":"2018","journal-title":"Anal. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djj206","article-title":"Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors","volume":"98","author":"Grosch","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa061652","article-title":"Celecoxib for the prevention of colorectal adenomatous polyps","volume":"355","author":"Arber","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"djw151","DOI":"10.1093\/jnci\/djw151","article-title":"Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial","volume":"108","author":"Thompson","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1158\/1078-0432.CCR-13-2305","article-title":"COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis","volume":"20","author":"Gallouet","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_21","first-page":"1088","article-title":"Celecoxib enhances the radiosensitivity of HCT116 cells in a COX-2 independent manner by up-regulating BCCIP","volume":"9","author":"Xu","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1096\/fj.01-0299fje","article-title":"COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib","volume":"15","author":"Grosch","year":"2001","journal-title":"FASEB J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","article-title":"Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging","volume":"78","author":"Que","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e125476","DOI":"10.1172\/jci.insight.125476","article-title":"Skin cancer precursor immunotherapy for squamous cell carcinoma prevention","volume":"4","author":"Rosenberg","year":"2019","journal-title":"JCI Insight"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/1389450119666180803121737","article-title":"Celecoxib in Cancer Therapy and Prevention\u2014Review","volume":"20","author":"Nowaszewska","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/0717-6287-47-27","article-title":"Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy","volume":"47","author":"Rosas","year":"2014","journal-title":"Biol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1615\/JEnvironPatholToxicolOncol.2016015704","article-title":"Chemoprevention of Colon Cancer through Inhibition of Angiogenesis and Induction of Apoptosis by Nonsteroidal Anti-Inflammatory Drugs","volume":"35","author":"Ghanghas","year":"2016","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"key":"ref_28","first-page":"132","article-title":"Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity","volume":"69","author":"Li","year":"2014","journal-title":"Pharmazie"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jso.23538","article-title":"Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: A phase II TCOG study","volume":"109","author":"Wang","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/jnci\/djq442","article-title":"Chemoprevention of nonmelanoma skin cancer with celecoxib: A randomized, double-blind, placebo-controlled trial","volume":"102","author":"Elmets","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Torres-Collado, A.X., and Jazirehi, A.R. (2018). Overcoming Resistance of Human Non-Hodgkin\u2019s Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors. Cancers, 10.","DOI":"10.3390\/cancers10060200"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2016.10.016","article-title":"Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth","volume":"385","author":"Gowda","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e8857","DOI":"10.1097\/MD.0000000000008857","article-title":"Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer","volume":"96","author":"Guo","year":"2017","journal-title":"Medicine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2217\/fon.12.196","article-title":"Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients","volume":"9","author":"Perroud","year":"2013","journal-title":"Future Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/jnci\/djh322","article-title":"Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells","volume":"96","author":"Liu","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"21544","DOI":"10.1074\/jbc.M114.558890","article-title":"Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib","volume":"289","author":"Edagawa","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/2193-1801-3-495","article-title":"The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma","volume":"3","author":"Reis","year":"2014","journal-title":"Springerplus"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/jid.2010.40","article-title":"Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac\/hyaluronic acid correlates with downregulation of c-FLIP","volume":"130","author":"Fecker","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.canlet.2006.11.032","article-title":"Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt\/GSK3beta\/NAG-1 pathway","volume":"251","author":"Pang","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11115","DOI":"10.1158\/0008-5472.CAN-06-2471","article-title":"Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bbamcr.2010.09.016","article-title":"Involvement of caspase-9 in autophagy-mediated cell survival pathway","volume":"1813","author":"Jeong","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/40657","article-title":"Inhibition of death receptor signals by cellular FLIP","volume":"388","author":"Irmler","year":"1997","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/40901","article-title":"X-linked IAP is a direct inhibitor of cell-death proteases","volume":"388","author":"Deveraux","year":"1997","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-07-0136","article-title":"OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms","volume":"13","author":"Zhang","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_45","first-page":"319","article-title":"Celecoxib-induced apoptosis in acute promyelocytic leukemia cell line MR2 and its mechanism","volume":"36","author":"Xu","year":"2007","journal-title":"J. Zhejiang Univ. Med. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","article-title":"Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage","volume":"42","author":"Karimian","year":"2016","journal-title":"DNA Repair"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejca.2005.11.009","article-title":"Celecoxib leads to G2\/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner","volume":"42","author":"Kazanov","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_48","first-page":"41","article-title":"COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis","volume":"18","author":"Yamanaka","year":"2006","journal-title":"Int. J. Mol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/jid.2008.363","article-title":"Mcl-1 functions as major epidermal survival protein required for proper keratinocyte differentiation","volume":"129","author":"Sitailo","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1158\/0008-5472.CAN-06-0325","article-title":"Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma","volume":"66","author":"Kern","year":"2006","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1600-0625.2012.01516.x","article-title":"Activation of mitochondrial apoptosis pathways in cutaneous squamous cell carcinoma cells by diclofenac\/hyaluronic acid is related to upregulation of Bad as well as downregulation of Mcl-1 and Bcl-w","volume":"21","author":"Rodust","year":"2012","journal-title":"Exp. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.bbrc.2007.03.034","article-title":"Involvement of up-regulation of PUMA in non-steroidal anti-inflammatory drug-induced apoptosis","volume":"356","author":"Ishihara","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.bcp.2009.09.022","article-title":"New caspase-independent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue","volume":"79","author":"Franke","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bcp.2018.05.013","article-title":"Celecoxib inhibits mitochondrial O2 consumption, promoting ROS dependent death of murine and human metastatic cancer cells via the apoptotic signalling pathway","volume":"154","author":"Pritchard","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1002\/lary.26309","article-title":"Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production","volume":"127","author":"Sung","year":"2017","journal-title":"Laryngoscope"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12645-011-0017-5","article-title":"Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model","volume":"2","author":"Perumal","year":"2011","journal-title":"Cancer Nanotechnol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1474-8673.2006.00391.x","article-title":"Potential antioxidant activity of celecoxib and amtolmetin guacyl: In vitro studies","volume":"27","author":"Kirkova","year":"2007","journal-title":"Auton. Autacoid Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s10120-017-0720-y","article-title":"Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)","volume":"20","author":"Shitara","year":"2017","journal-title":"Gastric Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","article-title":"ROS in cancer therapy: The bright side of the moon","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"600","DOI":"10.14423\/SMJ.0000000000001166","article-title":"Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab","volume":"113","author":"Bukamur","year":"2020","journal-title":"South Med. J."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/7\/3622\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:10:43Z","timestamp":1760364643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/7\/3622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["ijms22073622"],"URL":"https:\/\/doi.org\/10.3390\/ijms22073622","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]}}}